Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

Novel pathways in the treatment of major depression: Focus on the glutamatergic system / Tomasetti, C.; Montemitro, C.; Fiengo, A. L. C.; Santone, C.; Orsolini, L.; Valchera, A.; Carano, A.; Pompili, M.; Serafini, G.; Perna, G.; Vellante, F.; Martinotti, G.; Giannantonio, M. D.; Kim, Y. -K.; Nicola, M. D.; Bellomo, A.; Ventriglio, A.; Fornaro, M.; Berardis, D. D.. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 25:4(2019), pp. 381-387. [10.2174/1381612825666190312102444]

Novel pathways in the treatment of major depression: Focus on the glutamatergic system

Tomasetti C.;Fiengo A. L. C.;Carano A.;Fornaro M.;
2019

Abstract

Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.
2019
Novel pathways in the treatment of major depression: Focus on the glutamatergic system / Tomasetti, C.; Montemitro, C.; Fiengo, A. L. C.; Santone, C.; Orsolini, L.; Valchera, A.; Carano, A.; Pompili, M.; Serafini, G.; Perna, G.; Vellante, F.; Martinotti, G.; Giannantonio, M. D.; Kim, Y. -K.; Nicola, M. D.; Bellomo, A.; Ventriglio, A.; Fornaro, M.; Berardis, D. D.. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 25:4(2019), pp. 381-387. [10.2174/1381612825666190312102444]
File in questo prodotto:
File Dimensione Formato  
Novel Pathways in the Treatment of Major Depression - Focus on the Glutamatergic System.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 288.88 kB
Formato Adobe PDF
288.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/801356
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact